Mahaveer Infoway (539383)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trading below book value: P/B 0.98, with price ₹7.75 against book value ₹7.93.
• Sales growth is still positive at 6.25%, showing some top-line resilience.
• ROCE is positive at 5.35%, indicating the existing capital base generates some operating return.
• Latest quarter sales of ₹1 Cr show the business is still operationally active.
• The stock is near its 52-week low, reducing the price paid relative to recent levels.

Concerns

• Profit growth is deeply negative at -61.54%, and latest quarter net profit is ₹0 Cr, showing negligible earnings power.
• ROE is negative at -1.45%, meaning the company is not earning a return on shareholder equity.
• No dividend is paid, offering no income compensation while waiting for a turnaround.
• Piotroski F-Score of 4/9 suggests weak financial health and poor fundamental discipline.

AI Analysis

Let's look at Mahaveer Infoway with cold eyes. A market capitalisation of just ₹4 Cr makes this a nano-cap, and size itself is a warning: small companies can vanish before they get noticed. The price is ₹7.75 while book value is ₹7.93, so on the surface I am buying a rupee of assets for 98 paise. But a low price-to-book is only meaningful if the assets earn an adequate return. Here, return on equity is -1.45% and return on capital employed is just 5.35%. As a shareholder, I am not being paid to wait: there is no dividend, and the latest quarter shows net profit of ₹0 Cr on sales of ₹1 Cr. Profit growth has collapsed by 61.54% despite sales growing 6.25% — that tells me margins are under severe pressure, or there are one-off costs, but either way the earnings power is missing. The Piotroski F-score of 4/9 reinforces my caution; this is not a financially improving business. Graham would say price is less than book, but he would also demand a clear margin of safety in earnings and a satisfactory record of stable profits. Mahaveer fails that test. The 52-week range of ₹7.10 to ₹15.88 shows how brutally this stock has fallen; value traps look cheap. I need proof of turnaround before committing capital. This is an asset play, not a compounder. I would only be interested if management can lift ROE above a meaningful hurdle, sustain positive net profits, and maintain the balance sheet without hidden debt. Until then, cheap can become cheaper.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer